2024 Vaccination Schedule: 0-18 Years of Age

  1. Hepatitis B (HepB) vaccine. (Min age: birth)
At birth:

• HBsAg-negative mother: administer 1 dose of monovalent HepB vaccine within 24hrs of birth for all medically stable infants ≥2000g. For infants <2000g, give 1 dose at chronological age 1 month or hospital discharge (whichever is earlier even if weight remains <2000g).

• HBsAg-positive mother: administer 1 dose of monovalent HepB vaccine and hepatitis B immune globulin (HBIG) within 12hrs of birth, regardless of birth weight. For infants <2000g, administer 3 more doses of vaccine (4 total) beginning at age 1 month. Test for HBsAg and antibody to HBsAg (anti-HBs) at age 9–12mos or 1–2mos after final dose if the series was delayed.

• Unknown HBsAg status: administer monovalent HepB vaccine within 12hrs of birth, regardless of birth weight. For infants <2000g, add HBIG within 12hrs of birth, and 3 more doses of vaccine (4 total) beginning at age 1 month. For infants weighing ≥2000g, determine mother’s HBsAg status as soon as possible and, if she is HBsAg-positive, also give HBIG as soon as possible but no later than age 1wk. If HBsAg-positive or status remains unknown, test for HBsAg and anti-HBs at age 9–12mos or 1–2mos after final dose if the series was delayed.

   Doses after the birth dose:

• The 2nd dose should be administered at age 1–2mos and the 3rd dose at 6–18mos. Monovalent HepB vaccine should be used for doses administered before age 6wks.

• Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine as soon as feasible.

• The minimum interval is 4wks for the 1st and 2nd dose, 8wks for the 2nd and 3rd dose, and 16wks for the 1st and 3rd dose (if 4 doses, substitute 4th dose for 3rd dose in these calculations). The final (3rd or 4th) dose in the HepB vaccine series should be administered no earlier than age 24wks.

• Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing HepB is administered after the birth dose.

• Revaccination may be recommended for: infants born to HBsAg-positive mothers, hemodialysis patients, or other immunocompromised persons.

• For catch-up vaccination recommendations, refer to the 2024 Catch-Up Vaccination Schedule: 4 Months–18 years chart.

  2. Rotavirus (RV) vaccine. (Min age: 6wks for both RV1 [Rotarix] and RV5 [RotaTeq])

• Administer a series of RV vaccine to all infants as follows:

1. If Rotarix is used, administer a 2-dose series at 2 and 4mos of age.

2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6mos.

3. If any dose in the series is either RotaTeq or unknown, default to 3-dose series.

  3. Diphtheria, tetanus, and acellular pertussis (DTaP) vaccine. (Min age: 6wks. Exception: DTaP-IPV [Kinrix, Quadracel]: 4yrs)

• Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15−18mos, and 4−6yrs. The 4th dose may be administered as early as age 12mos, provided at least 6mos have elapsed since the 3rd dose. If the 4th dose was inadvertently given as early as 12mos, it may be counted if given ≥4mos after the 3rd dose.

• 5th dose of DTaP vaccine is not needed if 4th dose was given at age ≥4yrs and ≥6mos after 3rd dose.

• For wound management in children age <7yrs with ≥3 doses of tetanus-toxoid-containing vaccine, administer DTaP for all wounds except clean and minor wounds if >5yrs since last dose of tetanus-toxoid-containing vaccine.

  4. Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age: 6wks for PRP‑T [ActHIB, Hiberix], PRP‑OMP [PedvaxHIB], DTaP‑IPV/Hib [Pentacel], DTaP-IPV-Hib-HepB [Vaxelis])

• Administer a 4-dose Hib vaccine series at 2, 4, and 6mos, then a booster dose at 12−15mos for ActHIB, Hiberix, Pentacel, or Vaxelis. Do not use Vaxelis as a booster dose; use a different Hib-containing vaccine. For PedvaxHIB, administer a 3-dose series at 2 and 4mos, then a booster dose at 12−15mos.

• For catch-up vaccination recommendations, refer to the 2024 Catch-Up Vaccination Schedule: 4 Months−18 years chart.

• Persons with high-risk conditions: refer to the ACIP 2024 Immunization Schedule footnotes.

  5. Pneumococcal vaccines. (Min age: 6wks for PCV15 and PCV20, 2yrs for PPSV23)
Routine vaccination with PCV:

• Administer a 4-dose series of PCV vaccine at ages 2, 4, 6mos and at age 12−15mos.

• Either PCV15 or PCV20 can be used for PCV vaccination. PCV20 is not indicated in healthy children if previously received 4 doses of PCV13 or PCV15 or another complete PCV series.

• Persons with high-risk conditions: refer to the ACIP 2024 Immunization Schedule footnotes.

  6. Inactivated poliovirus vaccine (IPV). (Min age: 6wks)

• Administer a 4-dose series of IPV at ages 2, 4, 6−18mos and 4−6yrs. The final dose in the series should be administered on or after the 4th birthday and at least 6mos after the previous dose.

• If ≥4 doses of IPV-containing combination vaccine are given before age 4yrs, an additional dose should be given on or after the 4th birthday and ≥6mos after the previous dose.

• If both trivalent OPV (tOPV) and IPV were given as part of a series, a total of 4 doses should be given to complete the series. Doses should be at least 4wks apart, with the final dose given on or after the 4th birthday and at least 6mos after the previous dose. If only OPV were given, and all doses given before 4yrs of age, 1 dose of IPV should be given at age ≥4yrs, at least 6mos after last OPV dose.

• Only tOPV counts toward the US vaccination requirements. Doses of OPV given before 4/1/2016 should be counted (unless noted as given during a campaign). Doses of OPV given on or after 4/1/2016 should not be counted.

• Unvaccinated or incompletely vaccinated adolescents age 18yrs should receive remaining IPV doses to complete a 3-dose primary series. Those who completed the primary series and remains at risk may receive one lifetime IPV booster.

  7. Influenza vaccines. (Min age: 6mos for inactivated influenza vaccine [IIV4], 2yrs for live attenuated influenza vaccine [LAIV4], 18yrs for recombinant influenza vaccine [RIV4])

• For the 2023–2024 season, administer 2 doses at least 4wks apart to children 6mos–8yrs who have not previously received ≥2 doses of influenza vaccine before July 1, 2023, or whose influenza vaccination history is unknown. Administer 1 dose if previously received ≥2 doses before July 1, 2023.

• Administer 1 dose for all children age ≥9yrs.

• Children with allergy to eggs can receive any influenza vaccine (egg-based and non-egg-based) appropriate for age and health status.

• Contraindications and precautions for influenza vaccines: refer to the ACIP 2024 Immunization Schedule footnotes or the product labeling.

  8. Measles, mumps, and rubella (MMR) vaccine. (Min age: 12mos)

• Administer a 2-dose series of MMR vaccine at ages 12−15mos and 4−6yrs.

• MMR (doses ≥4wks apart) or MMRV (doses ≥3mos apart) may be administered. For the 1st dose in ages 12–47mos, a separate MMR and varicella vaccine is recommended, unless MMRV preferred. The maximum age for MMRV is 12yrs.

• Administer 1 dose of MMR to infants aged 6−11mos before departure from the U.S. for international travel. These children should be revaccinated with 2 doses, the 1st at age 12−15mos (12mos for children in high-risk areas), and the 2nd dose at least 4wks later. Unvaccinated children ≥12mos should receive 2 doses at least 4 wks apart before departure.

  9. Varicella (VAR) vaccine. (Min age: 12mos)

• Administer a 2-dose series of VAR vaccine at ages 12−15mos and 4−6yrs. The 2nd dose may be administered as early as 3mos after the 1st dose. If the 2nd dose was given at least 4wks after the 1st dose, it can be accepted as valid.

• VAR or MMRV may be administered. For the 1st dose in ages 12–47mos, a separate MMR and varicella vaccine is recommended, unless MMRV preferred. The maximum age for MMRV is 12yrs.

10. Hepatitis A (HepA) vaccine. (Min age: 12mos)

• Initiate the 2-dose HepA vaccine series, separated by ≥6mos beginning at age 12–23mos.

• Administer 1 dose of HepA vaccine to infants aged 6–11mos before departure to countries with high or intermediate HepA endemicity; revaccinate with 2 doses, ≥6mos apart, between age 12–23mos. Unvaccinated children aged ≥12mos should receive 1 dose as soon as travel is considered.

• For catch-up vaccination recommendations, refer to the 2024 Catch-Up Vaccination Schedule: 4 Months–18 years chart.

11. Meningococcal vaccines. (Min age: 2mos for MenACWY-CRM [Menveo], 2yrs for MenACWY-TT [MenQuadfi], 10yrs for serogroup B meningococcal [MenB] vaccines: MenB-4C [Bexsero] and MenB-FHbp [Trumenba], 10yrs for MenACWY-TT/MenB-FHbp [Penbraya])

• MenACWY vaccination (Menveo, MenQuadfi): 

— Administer a 2-dose series at 11−12yrs and 16yrs.

— Administer 1 dose to 1st-year college students living in residential housing (if not previously vaccinated at ≥16yrs) or military recruits.

— Children who received MenACWY before age 10yrs and for whom boosters are recommended due to ongoing increased meningococcal risk should follow the booster schedule for persons at increased risk. If boosters are not recommended, administer routine vaccination at 11−12yrs and 16yrs.

— Menveo is available in 2 formulations (lyophilized and liquid). The liquid formulation should not be used before age 10yrs.

• MenB vaccination (Bexsero, Trumenba):

— Persons 16−23yrs (16−18yrs preferred) not at increased risk may receive, based on shared clinical decision-making, 2 doses of Bexsero at least 1 month apart or 2 doses of Trumenba at least 6mos apart (if 2nd Trumenba dose given too soon, administer a 3rd dose at least 4mos after the 2nd dose).

— Bexsero and Trumenba are not interchangeable; use the same product for all doses in a series.

• MenACWY and MenB vaccines may be given simultaneously but at different anatomic sites, if feasible.

• Children age ≥10yrs may receive 1 dose of Penbraya as an alternative to separate administration of MenACWY and MenB when both vaccines would be given on the same clinic day.

— Children not at increased risk: if Penbraya is used for 1st dose of MenB, Trumenba should be given for 2nd dose.

— Children at increased risk: Penbraya may be used for additional MenACWY and MenB doses (including booster). The interval between Penbraya doses is ≥6mos.

• Persons with high-risk conditions or those traveling to or living in countries where meningococcal disease is hyperendemic or epidemic: refer to the ACIP 2024 Immunization Schedule footnotes.

• Additional information on MenACWY and MenB booster doses in special situations is available at https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

12. Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine. (Min age: 11yrs for routine vaccination, 7yrs for catch-up)

• Give 1 dose of Tdap (adolescent booster) at age 11–12yrs.

• Tdap can be administered regardless of the interval since the last tetanus and diphtheria toxoid-containing vaccine.

• Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferably during the early part of gestational weeks 27–36).

• For catch-up vaccination recommendations, refer to the 2024 Catch-Up Vaccination Schedule: 4 Months−18 years chart.

• For wound management in children age ≥7yrs with ≥3 doses of tetanus-toxoid-containing vaccine, administer Tdap or Td for clean and minor wounds if >10yrs since last dose of tetanus-toxoid-containing vaccine. For all other wounds, administer Tdap or Td if >5yrs since last dose of tetanus vaccine. Tdap is preferred for age ≥11yrs with no or unknown history of Tdap vaccination, or in pregnancy.

13. Human papillomavirus (HPV) vaccines. (Min age: 9yrs for 9vHPV [Gardasil 9])

• Adolescents age 11−12yrs (can start at age 9yrs) and through 18yrs (if not previously adequately vaccinated) should receive HPV vaccine series. Number of doses is dependent on age at initial vaccination:

— Initiated at age 9−14yrs: administer a 2-dose series at 0, 6–12mos. The minimum interval between doses is 5mos; repeat dose if given too soon.

— Initiated at age ≥15yrs: administer a 3-dose series at 0, 1−2, and 6mos. The 1st and 2nd dose should be at least 4wks apart, the 2nd and 3rd dose at least 12wks apart, and the 1st and 3rd dose at least 5mos apart; repeat dose if given too soon.

• No additional doses are needed for persons who have completed a valid series with any HPV vaccine.

• Administer HPV vaccine beginning at age 9yrs to children with any history of sexual abuse or assault.

• Immunocompromised children should receive a 3-dose series at 0, 1−2, and 6mos, regardless of age at vaccine initiation.

• HPV vaccination is not recommended for pregnancy. However, pregnancy testing is not needed before vaccination. If found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the series should be delayed until completion of pregnancy.

14. Dengue vaccine (Min age: 9yrs for DEN4CYD [Dengvaxia])

• Give 3 doses at 0, 6, 12mos in persons age 9−16yrs who live in dengue endemic areas and have laboratory-confirmed previous dengue infection.

• Children traveling to or visiting dengue endemic areas should not be vaccinated.

15. Covid-19 vaccines (Min age: 6mos for Moderna and Pfizer-BioNTech vaccines; 12yrs for Novavax vaccine)

• ACIP recommends use of COVID-19 vaccines for everyone ages ≥6mos.

• Unvaccinated children and those previously vaccinated with any Original monovalent or bivalent COVID-19 vaccine (Janssen, Moderna, Novavax, Pfizer-BioNTech) should receive age-appropriate doses of the updated 2023-2024 formulation (no preferential recommendation for the use of any one vaccine over another).

• The Novavax vaccine remains authorized for use as a 2-dose primary series in children age ≥12yrs.

• The Original monovalent and bivalent (Original and Omicron BA.4/BA.5) formulations should no longer be used for vaccination. The Janssen vaccine is no longer available in the US.

• For a list of currently available COVID-19 vaccines and other recommendations for COVID-19 vaccination including dosing for immunocompromised adults, see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html.

16. Respiratory syncytial virus (RSV vaccine, RSV-mAb). (Min age: birth for nirsevimab [Beyfortus])

• Either maternal RSV vaccination with Abrysvo or infant immunization with nirsevimab is recommended to prevent RSV lower respiratory tract infection in infants.

• Infants: give 1 dose of nirsevimab; timing of administration is dependent on birth month (RSV seasonality) and mother’s RSV vaccination status. Nirsevimab can be given to children who are eligible to receive palivizumab. If previously received nirsevimab, palivizumab should not be given for the same RSV season.

• Pregnant persons: give 1 dose of RSV vaccine Abrysvo at 32wks 0 days through 36wks 6 days gestation from September through January, regardless of previous RSV infection. There is currently no recommendation for RSV vaccination in subsequent pregnancies.

17. Mpox vaccine (Min age: 18yrs for Jynneos)

• Give a 2-dose series, 28 days apart, to persons age 18yrs and at risk for mpox infection.